Self-reported poor sleep quality (PSQI \>5) at screening
Self-reported nocturnal leg cramp averaging ≥4 episodes per fortnight at screening
Capacity to understand and provide electronic informed consent
Willing to wear an Oura Ring wearable device continuously throughout the study period
Access to a smartphone/tablet with iOS 15 or higher and Android 9 or higher and willing to install and use the Oura and Trialflare applications
Be a resident of and permanently living in Florida with no planned travel across more than one time zone for at least 1 night during the study period
You may not be if
Current or recent (within 4 weeks of randomisation) use of melatonin, magnesium, or other supplements specifically taken for sleep or leg cramps or listed as an ingredient of the intervention supplement.
Known or suspected secondary cause of nocturnal leg cramps (e.g. peripheral vascular disease, neurological condition, renal impairment, thyroid disorder)
Any current or prior diagnosis of:
Cancer or malignancy of any kind (prior malignancy is not exclusionary if the participant is in confirmed remission and has completed all treatment)
